Trial Profile
An Open-label, Randomised, Crossover Study to Assess the Relative bioavailability of Different 2mg Formulations of GSK2018682 (S1P1 Agonist) in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 2018682 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 08 Nov 2011 New trial record